News
Roivant logo

Roivant joins RNA splicing push with Eisai deal

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugm

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

Partner Content

Partner Content
LEAP HR: Life Sciences Europe
Partner Content

LEAP HR: Life Sciences Europe

Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences